Hopes dashed, shares slashed: Adagio drug looks ill-suited to omicron

Just two weeks ago, Adagio Therapeutics Inc. CEO Tillman Gerngross was confident that his company’s experimental antibodies would "neutralize SARS-CoV-2 and all its known variants." New data suggest otherwise.